OR WAIT null SECS
April 28, 2016.
The market for hematological cancers, covering leukemia, lymphoma and myeloma, is expected to more than double from $30.7 billion in 2015 to $70.1 billion by 2022, according to GBI Research.
The company's report states that patent expirations for drugs including Rituxan, Gleevec and Velcade will be "counteracted by recently approved drugs and pipeline products" GBI analyst Yasser Mushtaq points to Keytruda (pembrolizumab), for example, "which is already marketed for metastatic melanoma, is in Phase III development for multiple myeloma and refractory multiple myeloma". It is also in Phase II development for a number of lymphomas and will therefore contribute to market revenue over coming years.
Mushtaq adds: “A number of drugs currently not marketed will also develop into blockbuster drugs, including selinexor, venetoclax, KTEC-19, and polatuzumab vedotin. Venetoclax in particular is expected to be very lucrative, hitting sales of $3.5 billion in 2022, up from an estimated $155.2 million in 2016. It is a selective, orally administered, first-in-class small molecule therapy in development by AbbVie and Roche, and is indicative of a trend in the market towards expensive targeted therapies, including monoclonal antibodies (mAbs).”